- Pressure
BioSciences was described as an integral part of women’s cancer research
efforts during a presentation last month at the International Gynecologic
Cancer Society conference in Brazil
- The
company’s patented pressure cycling technology provided a key link in a
trio of procedures for analyzing biopsied cells
- Gynecologic
cancers are diagnosed in the United States at a rate of nearly 100,000
women per year, and the global gynecological cancer drug market is
expected to generate revenues of more than $41.8 billion by 2026
A new, novel workflow for the analysis of proteins from
cancer biopsy samples was recently disclosed at a major international
gynecologic cancer meeting. This innovative workflow is expected to markedly
enhance cancer diagnosis, prognosis and effective treatment therapies. The
revelation of this new workflow has augmented the reputation of Pressure
BioSciences Inc. (OTCQB: PBIO) amid the modern science rush to build
better precision medicine for malignancies that claim hundreds of thousands of
lives each year in the United States alone (http://ibn.fm/vawZS).
Human biology is complex, but scientific advances in the
field of big data analysis have provided remarkably advanced tools for
attempting repairs on the constellation of minuscule pieces of the human
machine that may break down.
Efforts to develop an optimal means of analyzing proteins
from cancer biopsy samples led one group of top gynecologic researchers to a
new, innovative workflow that utilizes Pressure BioSciences’ patented pressure
cycling technology (PCT) platform as the bridging mechanism in a process that
begins with Leica Microsystems’ laser microdissection (LMD) platform and ends
with comprehensive analysis on a ThermoFisher Scientific mass spectrometry (MS)
instrument.
Pressure BioSciences’ PCT platform, as an integral part of
the analytical trio, prepares the excised cells for micro-scale quantitative
proteomics and phosphoproteomics – the large-scale study of proteins and their
phosphorylation-based signaling networks – by provoking rapid and efficient
high-quality cellular protein release and preparation from the biopsy samples.
The entire sample preparation process is done in the company’s proprietary
Barocycler 2320EXT system.
The researchers presented an explanation of their working
process in searching for ways to combat gynecological cancers during a core
session of the annual International Gynecologic Cancer Society (“IGCS”)
conference last month in Rio de Janeiro, Brazil. Dr. Larry Maxwell, a
gynecologic oncologist and the OB-GYN chairman at Northern Virginia’s Inova
Fairfax Hospital, described the PCT-based Barocycler system technology provided
by Pressure BioSciences as “an essential requirement for our novel workflow in
meeting our goals” in his presentation to the IGCS.
“The conventional use of chemotherapy in ovarian cancer
treatment is being rapidly replaced by biologic therapeutics that target the
cancer (the ‘seed’) and also the micro-environment (the ‘soil’) in which it
grows,” Maxwell stated in a news release (http://ibn.fm/fo6x7). “Being able to collect small
tissue specimens and characterize them across multiple genomic and proteomic
platforms will enable us to markedly enhance our ability to develop companion
diagnostics and prognostics as well as identify targets for future therapeutic
strategies.”
Protein chemist Dr. Thomas Conrads, the senior director of
women’s health research at the Inova Women’s Hospital, added, “We believe that
the insights we gain from applying this novel workflow will result in
significant improvements in the clinical management of gynecologic cancer.”
Gynecologic cancers are diagnosed at a rate of nearly
100,000 women per year in the United States (http://ibn.fm/koVZR). Aurora Healthcare estimates that more
than 30,000 of those patients die each year (http://ibn.fm/EezJZ). Publication The Pharma Letter,
citing analysis by Persistence Market Research Report, states that the
worldwide market for gynecological cancer drugs is expected to expand at a CAGR
of 6.2 percent between 2018 and 2026, generating revenues of more than $41.8
billion (http://ibn.fm/aeE8t),
with most of the costs led by the United States. The importance of effective
therapies in terms of life-saving measures and product costs is apparent, and
it serves as an indicator of PBIO technology’s potential attractiveness to
other research labs.
Pressure BioSciences continues adding a number of
significant achievements to underscore the reputation of its technology.
Recently, the company announced an agreement with a world-renowned,
multibillion-dollar biotherapeutics firm that will use PBIO’s proprietary
BaroFold(TM) technology to improve the manufacture of a protein drug (http://ibn.fm/KaqJ1).
Protein-based therapeutics are a growing part of the global health care
industry, which is projected to reach nearly $249 billion in revenues by next
year, according to Research and Markets analysis (http://ibn.fm/RIKAI).
For more information, visit the company’s website at www.PressureBioSciences.com
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
